Patient Profile: A 68-Year-Old Woman With HER2+ Metastatic Breast Cancer

Expert oncologist Virginia Kaklamani, MD, DSc, shares her perspectives on a patient case of HER2+ metastatic breast cancer (mBC) treated with multiple lines of therapy.

Related Keywords

,Improving Outcomes ,Breast Cancer ,Translating Evidence ,Clinical Practice ,Year Old Woman With ,Metastatic Breast Cancer ,Virginia Kaklamani ,Her2 Positive ,Her2 Breast Cancer ,Ild ,Interstitial Lung Disease ,Thp Therapy ,Udocetaxel ,Btrastuzumab ,Pertuzumab ,Cleopatra Trial ,Cleopatra Regimen ,Cleopatra Study ,Trastuzumab Deruxtecan ,Tdxd ,T Dxd ,Destiny Breast03 ,Tdm1 ,Trastuzumab Emtansine ,Tucatinib ,Capecitabine ,Third Line Therapy ,Third Line Treatment ,Later Line Therapy ,Her2climb ,Her2climb Trial ,Brain Mets ,Brain Metastases ,